OncoSil Raises Institutional Capital via Share Placement and Issues Cleansing Notice

OncoSil Medical Ltd ( (AU:OSL) ) has issued an announcement.

OncoSil Medical has raised new equity by issuing 4,100,470 fully paid ordinary shares at $0.68 each to sophisticated and institutional investors via a placement, providing additional capital to support its interventional oncology business. The shares were issued without a prospectus under Australian disclosure exemptions, with the company confirming compliance with its financial reporting and continuous disclosure obligations under the Corporations Act.

The cleansing notice confirms that no excluded information is being withheld from the market, aiming to ensure that the newly issued shares can be freely traded and that existing and new investors have a level information playing field. The move reinforces OncoSil’s access to institutional capital as it continues commercial rollout of its pancreatic cancer device portfolio in key global markets, potentially strengthening its financial position and strategic flexibility.

The company’s leadership authorised the announcement, signalling board-level support for the capital management initiative and its alignment with broader corporate objectives. By tapping sophisticated and institutional investors, OncoSil also underscores ongoing professional investor interest in its specialised oncology technology and international growth trajectory.

The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.

More about OncoSil Medical Ltd

OncoSil Medical is a global medical device company focused on interventional oncology, developing targeted intratumoural radiotherapy solutions to improve outcomes for cancer patients. Its flagship OncoSil device delivers Phosphorous-32 microparticles directly into unresectable locally advanced pancreatic tumours, and is approved or marketed in more than 30 countries including across the EU, UK, Türkiye and Israel.

The device has received CE Marking and breakthrough device designation in both Europe and the United States, reflecting its innovative approach to treating a cancer that is typically diagnosed late and carries poor long-term survival prospects. Commercial treatments using OncoSil have already been undertaken in several European markets, underscoring the company’s expanding international footprint in pancreatic cancer care.

Average Trading Volume: 61,650

Technical Sentiment Signal: Sell

Current Market Cap: A$13.22M

For an in-depth examination of OSL stock, go to TipRanks’ Overview page.